Supplementary Figure 1 from Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non–Small Cell Lung Cancer Patients
Supplementary Figure 1 entitled example of combined immunofluorescent staining and a three-color FA-FISH experiment using filtration enriched-H2228 cell line spiked into peripheral blood samples from a healthy donor and ALK break-apart probes coupled to the chromosome 2-specific centromeric probe.